FDA Panel Supports RP1 Evidence in Advanced Melanoma
The U.S. FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy results from the single-arm IGNYTE study of vusolimogene oderparepvec (RP1) plus nivolumab are evaluable and clinically meaningful in adults with…
